In CRC patients with POLE mutations, which are usually with MSS, elevated numbers of TIL, promoted PD-L1 expression, and upregulated production of cytotoxic T cell markers and effector cytokines indicate heightened tumor immunogenicity. This evidence concerns the gene CD274 and colorectal carcinoma.